MenüForum-NavigationForumMitgliederAnmeldenRegistrierenForum-Breadcrumbs - Du bist hier:ForumFlohmarkt: Allgemeines0jzhyaAntwortenAntworten: 0jzhya <blockquote><div class="quotetitle">Zitat von Gast am 31. März 2026, 14:53 Uhr</div>[url=https://www.researchgate.net/scientific-contributions/Zoya-N-Demidenko-39445053]Zoya Demidenko[/url]: Scientist in Tumor Science [url=https://search.sunbiz.org/Inquiry/CorporationSearch/SearchResults?InquiryType=EntityName&InquiryDirectionType=PreviousRecord&SearchTerm=RAPALLO%20ENTERPRISE%2C%20LLC&SearchNameOrder=RAPAN%20P050001591430&ListNameOrder=RAPAMULTISERVICES%20L220000371890&Detail=FL.DOS.Corporations.Shared.Contracts.FilingRecord]Zoya Demidenko[/url] is a distinguished researcher affiliated with the Unit of Cell Stress Science at Roswell Park Oncology Institute in Buffalo, New York. Previously, she conducted research at the NIH and New York Medical College, building a robust base in clinical study. Demidenko's academic output covers several key domains, including the PI3K/AKT/mTOR molecular pathway, cell cycle control, cell senescence, and malignancy biology. Currently, she has written over 46 peer-reviewed publications, which have garnered over 4,100 mentions — a testament to the impact of her findings. One of her most significant achievements lies in understanding the processes of biological cell aging. Her work showed that when the cell cycle is halted while cellular expansion continues, cells enter senescence. Crucially, [url=https://pmc.ncbi.nlm.nih.gov/articles/PMC3273895/]Zoya Demidenko[/url] demonstrated that this transition can be inhibited by medication using agents such as mTOR inhibitors. [url=https://moodylab.smhs.gwu.edu/lab-members]Zoya Demidenko[/url] has additionally contributed substantially to tumor management research, notably in the area of selective cell protection — a method designed to protecting non-cancerous cells from chemotherapy while leaving cancer cells exposed. This method carries major hope for diminishing the side effects of oncological therapy. Across her scientific life, Demidenko has collaborated with prominent researchers internationally, including Dr. Mikhail Blagosklonny. Her publications can be found in top-tier periodicals such as Oncotarget, Cell Cycle, Aging (Albany NY), and Oncogene. [31.03.2026 11:21] Папа: With an h-index of 33, [url=https://www.aging-us.com/article/100421/]Zoya Demidenko[/url] ranks as a widely cited figure in contemporary oncological research, whose findings go on to influence our understanding of how cells grow old, resist therapy, and how malignant disease may be more effectively targeted. https://pmc.ncbi.nlm.nih.gov/articles/PMC3273895/</blockquote><br> Abbrechen
